Your session is about to expire
← Back to Search
DT2216 for Cancer
Study Summary
This trial will test the safety and effectiveness of a new drug for cancer patients who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this medical experiment currently enrolling patients?
"Affirmative, the clinical trial is actively seeking participants. According to records stored on clinicialtrials.gov, this study was originally posted in August of 2021 and last updated in July 2022. In total, 24 individuals are expected to participate from 3 different medical locations."
What key objectives is this experiment hoping to accomplish?
"As declared by the clinical trial sponsor, Dialectic Therapeutics Inc., the primary objective of this 28 day experiment is to measure dose-limiting toxicity (DLT) in patients administered DT2216. Additionally, secondary objectives include gaining insight into platelet counts after administration of DT2216 and measuring Cmax levels and BCL-XL concentrations in peripheral blood mononuclear cells."
How many participants are currently enrolled in this clinical experiment?
"Affirmative. Records from clinicaltrials.gov demonstrate that the study, which was launched on August 25th 2021 and last revised on July 27th 2022, is presently recruiting participants from 3 distinct locations with a goal of 24 enrollees."
Has the FDA officially sanctioned DT2216 for clinical use?
"As this is an early phase 1 trial, there is still limited evidence of DT2216's efficacy and safety. As such, the Power team have assigned it a score of 1 on the scale from one to three."
Share this study with friends
Copy Link
Messenger